Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker Drug Class List
✉ Email this page to a colleague
Drugs in Drug Class: Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annora Pharma | IVABRADINE HYDROCHLORIDE | ivabradine hydrochloride | TABLET;ORAL | 213366-001 | Oct 5, 2022 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| Annora Pharma | IVABRADINE HYDROCHLORIDE | ivabradine hydrochloride | TABLET;ORAL | 213366-002 | Oct 5, 2022 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| Ingenus Pharms Llc | IVABRADINE HYDROCHLORIDE | ivabradine hydrochloride | TABLET;ORAL | 214051-001 | Dec 30, 2021 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| Zydus Pharms | IVABRADINE HYDROCHLORIDE | ivabradine hydrochloride | TABLET;ORAL | 213442-001 | Nov 29, 2023 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
